ONCOMINE COMPREHENSIVE MYELOID PANEL Test
Test Name: ONCOMINE COMPREHENSIVE MYELOID PANEL Test
Components: ABL1, ASXL1, BCOR, BAALC, BRAF, CALR, CEBPA, CBL, CSF3R, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2,IKZF1, JAK2, KIT, KRAS, MPL, MYD88,MYC, NPM1, NRAS,NF1, PTPN11,PHF6, PRPF8, RB1, RUNX1, SETBP1, SF3B1, SRSF2,SH2B3, SMC1A, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2, FUSION GENE -ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MLLT3, MLLT10, MECOM, MET, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3
Price: 6400.0 AED
Sample Condition: 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled NGS Test Requisition Formis mandatory.
Report Delivery: Sample by 1st / 16th of every month; Report 15th / 30th of Same month
Method: NGS
Test type: Leukemia
Doctor: Hematologist, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information: Duly filled NGS Test Requisition Formis mandatory.
Test Details: The Oncomine Comprehensive Myeloid Panel Test is a genetic test that analyzes a patient’s DNA to detect mutations that are commonly associated with myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and chronic myeloid leukemia (CML). The test uses next-generation sequencing technology to analyze a panel of genes that are known to be involved in the development and progression of myeloid disorders. The results of the test can help clinicians to diagnose and classify myeloid disorders, as well as to determine the most appropriate treatment options for individual patients.
Test Name | ONCOMINE COMPREHENSIVE MYELOID PANEL Test |
---|---|
Components | ABL1, ASXL1, BCOR, BAALC, BRAF, CALR, CEBPA, CBL, CSF3R, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2,IKZF1, JAK2, KIT, KRAS, MPL, MYD88,MYC, NPM1, NRAS,NF1, PTPN11,PHF6, PRPF8, RB1, RUNX1, SETBP1, SF3B1, SRSF2,SH2B3, SMC1A, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2,FUSION GENE -ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MLLT3, MLLT10, MECOM, MET, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3 |
Price | 6400.0 AED |
Sample Condition | 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled NGS Test Requisition Formis mandatory. |
Report Delivery | Sample by 1st / 16th of every month; Report 15th / 30th of Same month |
Method | NGS |
Test type | Leukemia |
Doctor | Hematologist, Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled NGS Test Requisition Formis mandatory. |
Test Details |
The Oncomine Comprehensive Myeloid Panel Test is a genetic test that analyzes a patient’s DNA to detect mutations that are commonly associated with myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and chronic myeloid leukemia (CML). The test uses next-generation sequencing technology to analyze a panel of genes that are known to be involved in the development and progression of myeloid disorders. The results of the test can help clinicians to diagnose and classify myeloid disorders, as well as to determine the most appropriate treatment options for individual patients. |